Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024GlobeNewsWire • 05/02/24
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 04/23/24
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of OsteosarcomaGlobeNewsWire • 04/09/24
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor EventsGlobeNewsWire • 04/03/24
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of OsteosarcomaGlobeNewsWire • 03/21/24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/29/24
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern TimeGlobeNewsWire • 02/22/24
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care TherapyGlobeNewsWire • 01/04/24
Lisata Therapeutics accelerates pancreatic cancer trial, expects early data in 2024Proactive Investors • 12/12/23
All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to BuyZacks Investment Research • 11/07/23
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern TimeGlobeNewsWire • 10/26/23
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating PeptideGlobeNewsWire • 10/24/23
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic CancerGlobeNewsWire • 10/17/23
Lisata Therapeutics Announces Participation in Upcoming Conferences in OctoberGlobeNewsWire • 09/28/23
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid TumorsGlobeNewsWire • 09/12/23